Purpose: To identify breast MR imaging biomarkers to predict histologic grade and receptor status of ductal carcinoma in situ (DCIS). Materials and Methods: Informed consent was waived in this Health Insurance Portability and Accountability Actcompliant Institutional Review Board-approved study. Case inclusion was conducted from 7332 consecutive breast MR studies from January 1, 2009, to December 31, 2012. Excluding studies with benign diagnoses, studies without visible abnormal enhancement, and pathology containing invasive disease yielded 55 MR-imaged pathology-proven DCIS seen on 54 studies. Twenty-eight studies (52%) were performed at 1.5 Tesla (T); 26 (48%) at 3T. Regions-of-interest representing DCIS were segmented for precontrast, first and fourth postcontrast, and subtracted first and fourth postcontrast images on the open-source three-dimensional (3D) Slicer software. Fifty-seven metrics of each DCIS were obtained, including distribution statistics, shape, morphology, Renyi dimensions, geometrical measure, and texture, using the 3D Slicer HeterogeneityCAD module. Statistical correlation of heterogeneity metrics with DCIS grade and receptor status was performed using univariate Mann-Whitney test. Results: Twenty-four of the 55 DCIS (44%) were high nuclear grade (HNG); 44 (80%) were estrogen receptor (ER) positive. Human epidermal growth factor receptor-2 (HER2) was amplified in 10/55 (18%), nonamplified in 34/55 (62%), unknown/equivocal in 8/55 (15%). Surface area-to-volume ratio showed significant difference (P < 0.05) between HNG and non-HNG DCIS. No metric differentiated ER status (0.113 < p 1.000). Seventeen metrics showed significant differences between HER2-positive and HER2-negative DCIS (0.016 < P < 0.050). Conclusion: Quantitative heterogeneity analysis of DCIS suggests the presence of MR imaging biomarkers in classifying DCIS grade and HER2 status. Validation with larger samples and prospective studies is needed to translate these results into clinical applications. Level of Evidence: 3 Technical Efficacy: Stage 3
D
uctal carcinoma in situ (DCIS), a preinvasive form of breast cancer, is characterized by the proliferation of malignant epithelial cells confined by a myoepithelial layer. 1 The term DCIS encompasses a variable spectrum of disease partly classified by its nuclear grade (low, intermediate, high). [1] [2] [3] Recent debates surrounding the optimal management of DCIS are based on the premise and data suggesting that high-grade DCIS progresses differently in its natural history and responds differently to treatment than low-grade DCIS. 4, 5 As such, active surveillance, rather than treatment, of low-grade DCIS has been proposed. 6 Research trials exploring surveillance as an alternative management to surgery are also under way. 7, 8 Currently, the definitive diagnosis of DCIS must be confirmed by surgical excision because DCIS may harbor foci of invasive cancer incompletely sampled at core needle biopsy. 9 It is the hope that MR imaging aided by computer-aided detection (CAD) may help decipher some of the varied biological behavior of DCIS without or before definitive surgical intervention.
Dynamic contrast-enhanced (DCE) MR imaging is at present the most sensitive modality in the detection of breast cancer including DCIS. [10] [11] [12] [13] [14] Research by Kuhl et al indicates that contrast enhancement on MR imaging itself represents an imaging biomarker of DCIS with higher nuclear grade. 14 Additionally, DCE MR imaging also allows for assessment of tumor heterogeneity, which can be quantified as phenotypic biomarkers of the disease. 15 Heterogeneity analysis of breast cancer has been largely performed with ultrasound and MR imaging. [15] [16] [17] [18] [19] [20] [21] [22] Previous studies using heterogeneity analysis in the development of MR imaging biomarkers focused on differentiating benign from malignant breast lesions and molecular subtypes of invasive breast cancer. [22] [23] [24] Recent applications of heterogeneity analysis
show promising results in the assessment of response of invasive breast cancer being treated with neoadjuvant therapy and the recurrence risk of invasive breast cancer. [25] [26] [27] [28] Our aim was to identify MR imaging biomarkers that can predict the nuclear grade and receptor status of DCIS, thereby providing noninvasive insight into its diverse tumor biology with potential implications for future management.
Materials and Methods

Case Selection
This study was Health Insurance Portability and Accountability Act-compliant and approved by our Institutional Review Board. Informed consent was waived given its retrospective design. Case selection was conducted from 7332 consecutive contrast-enhanced breast MR examinations (unilateral or bilateral) performed in 3864 women between January 1, 2009, and December 31, 2012. MR examinations with MR findings that subsequently underwent histopathologic sampling were included in the study. Review of the electronic medical records further excluded patients without the diagnosis of DCIS, cases of DCIS showing invasive or microinvasive disease, and patients without final pathology from surgical excision internally reviewed by our breast pathologists. Applying these exclusion criteria yielded 93 patients with 94 cases of DCIS (one patient with bilateral DCIS). Among these, four more cases were excluded after correlating with the pathology reports: one case of DCIS focally involving a papilloma; one case of carcinoma in situ with equivocal classification between DCIS and pleomorphic lobular carcinoma in situ (LCIS); one case of DCIS comprising two distinct cytomorphologies (low and high grades) within the same specimen; one case of DCIS without specified location in the mastectomy specimen and could not be correlated with the MR findings.
Of the remaining 89 patients with 90 cases of DCIS, 35 patients had MR imaging performed after surgical treatment and/ or after prior biopsies without definitive residual enhancement. These 35 patients were excluded, yielding a final study population of 54 patients (all women) with 54 MR examinations showing 55 cases of DCIS; one woman had bilateral DCIS visualized on her MR examination (Table 1) . Their ages at the time of diagnosis ranged from 26 to 79 with a median age of 49. No significant difference in age was found between 23/54 (43%) women with non-HNG DCIS and 31/54 (57%) women with HNG DCIS (P 5 0.22, Table 1 ). The woman with bilateral diseases had non-HNG DCIS in both breasts. Thirteen of the 55 cases of DCIS presented as residual enhancement on staging MR examinations after core biopsy diagnosis. Review of MR images and reports was performed by a breast-imaging fellow (S.S.C.) with the aid of a fellowship-trained radiologist with 12 years of breast MR imaging experience (E.C.G.).
Image Acquisition
Breast MR imaging during the study interval was acquired in prone position on a GE Signa 1.5 Tesla (T) scanner with a fourchannel GE dedicated breast surface coil (General Electric Healthcare, Milwaukee, WI) or a Siemens Trio 3T (Siemens Healthcare, Erlangen, Germany) scanner with a seven-channel dedicated breast surface coil (InVivo, Orlando, FL). From 2009 to 2012, 28 of the total 54 (52%) MR examinations were performed on a 1.5T scanner, and 26 of the 54 (48%) examinations were performed on a 3T scanner. DCE MR protocol included a three-plane localizing sequence, axial fat-suppressed T2-weighted fast spin-echo or short tau inversion recovery (STIR) sequence, and axial T1-weighted gradient-echo sequence before contrast agent administration.
Dynamic T1-weighted fat-suppressed three-dimensional (3D) fast spoiled gradient-echo sequences were performed before and at four time points after intravenous injection of 0.1 mmol/kg of gadopentetate dimeglumine (Magnevist; Bayer, Whippany, NJ) with an average temporal resolution of 90-100 s. Detailed parameters of the DCE 1.5T-MR protocol include 3D dynamically acquired pre-and post-contrast-enhanced T1-weighted fatsuppressed volumetric interpolated breath-hold examination (VIBE) sequences ( Dynamic images were acquired in the sagittal plane before 2010 and in the axial plane during/after 2010; delayed imaging was performed in the plane orthogonal to dynamic imaging. Sagittal image acquisition before 2010 uses similar imaging parameters as the above-mentioned 1.5T-MR protocol, using sagittally acquired volume imaging for breast assessment (VIBRANT) dynamic series (2.0 mm slice thickness, acquisition time 1 min 36 s). Postprocessing was routinely applied, including image subtraction, maximum intensity projection, and computer-aided detection (CADstream; Sectra, Linkoping, Sweden, or VersaVue; iCAD, Nashua, NH).
MR Features Data Collection
Each MR examination was prospectively interpreted and given a final BI-RADS assessment by a radiologist specialized in breast imaging. 29 Original radiology reports of all 54 MR examinations were reviewed by a breast-imaging fellow (S.S.C.) with the aid of a (32) 10 (18) (n/a in 3) Negative 21 (88) 13 (42) 34 (62) fellowship-trained radiologist with 12 years of breast MR imaging experience (E.C.G.). Data on MR features of the DCIS were extracted retrospectively from the radiology reports. Degree of background parenchymal enhancement (BPE; minimal, mild, moderate, and marked) and amount of fibroglandular tissue (FGT; fatty, scattered, heterogeneous, and extreme) were assigned prospectively based on the BI-RADS MR lexicon. 29 MR findings of the DCIS were interpreted prospectively as focus, mass, or nonmass enhancement (NME) based on the lesion enhancement type according to the BI-RADS classification. 29 Images of all 54 MR examinations were reviewed by the same breast-imaging fellow and fellowship-trained radiologist to verify that the recorded MR features correspond to the biopsy-proven DCIS.
Quantitative Analysis
The Digital Imaging and Communications in Medicine (DICOM) data of all 54 MR examinations were uploaded into an opensource image-processing and navigation software, 3D Slicer (Boston, MA). A breast-imaging fellow (S.S.C.) segmented the regions of interest (ROIs) on all slices semi-automatically based on the Otsu thresholding method, using the subtracted fourth postcontrast images. 30 The subtracted fourth postcontrast images were coregistered with the precontrast, first and fourth postcontrast, and subtracted first postcontrast images on 3D Slicer, thereby simultaneously providing the ROIs on the precontrast and other postcontrast sequences when segmentation was performed on the subtracted fourth postcontrast images. The 55 ROIs outlined the regions of enhancement representing the 55 cases of DCIS. Each ROI was visually verified and/or manually edited by the breastimaging radiology fellow (S.S.C.). The 3D image volume and label map that defined the ROIs were inputted into an open-source software module, HeterogeneityCAD (Boston, MA), 31 in 3D Slicer. The module quantified the heterogeneity of each ROI based on 57 metrics. 31 The metrics were categorized as first-order statistics, shape and morphology, texture, geometry, and Renyi dimensions. 31 First-order statistics included intensity values, skewness, variance, and kurtosis. Given that the signal intensity values did not take into consideration the MR transmitter gain, filter, and normalization process, percentages enhancement of the first and fourth postcontrast sequences based on mean intensity values were calculated and included as one of the metrics. Shape and morphological metrics included volume, surface area, compactness, and maximum 3D diameter. Texture metrics derived from gray-level co-occurrence matrix and gray-level run-length matrix quantified texture coarseness. Renyi dimensions, a generalization of fractal and box-counting dimension, were computed under the assumption that each ROI was a fractal. Complete description and definitions of the metrics with more in-depth references are available online at https://www.slicer.org/wiki/Documentation/Nightly/Modules/HeterogeneityCAD. 31 In total for each ROI, 57 numeric metric values were generated for each of its five imaging sequences: precontrast images, first postcontrast images, fourth postcontrast images, subtracted first postcontrast images, and subtracted fourth postcontrast images. 7, 32 Pathology reports of all specimens from core biopsy and surgical excisions were reviewed to confirm the worst pathologic assessment of each lesion. Estrogen receptor (ER) and progesterone receptor (PR) statuses were routinely tested on all DCIS at its initial diagnosis. Immunohistochemistry (IHC) stain for human epidermal growth factor receptor-2 (HER2) amplification in DCIS was routinely performed at our institution. However, no further analysis such as in situ hybridization was pursued when HER2 IHC results were equivocal. Presence of calcifications and necrosis was documented in the pathology reports and collated.
Histologic Assessments
Statistical Analysis
Clinical data such as patient demographics, MR descriptors, and DCIS features were compared between HNG and non-HNG DCIS using Student's t-test and Chi-square test. Statistical correlation of heterogeneity metrics with DCIS grade, ER status, and 
RESULTS
MR Descriptors
Just over a quarter of the 54 MR examinations (n 5 14/54; 26%) were performed for the purpose of routine high-risk screening; the majority of examinations (n 5 40/54; 74%) were obtained for diagnostic indications without a significant difference between the two groups of women with non-HNG versus HNG DCIS (P 5 0.12; Table 1 ). There was no significant difference in the time period during which the MR examinations were obtained between the non-HNG and HNG groups (P 5 0.20; Table 1 ). In addition, the field strengths (1.5T versus 3T scanners) of the MR examinations did not demonstrate any statistically significant difference between the non-HNG and HNG groups (P 5 0.43). Seven of 24 (30%) MR examinations in the non-HNG group had moderate or marked BPE, compared with 14 of 31 (45%) in the HNG group (P 5 0.42; Table 1 ). Fifteen of 24 (65%) MR examinations in the non-HNG group had heterogeneous or extreme amount of fibroglandular tissue, compared with 24 of 31 (77%) in the HNG group (P 5 0.54). Therefore, no significant differences were noted in the degree of BPE and the amount of fibroglandular tissue on MR examinations between the non-HNG and HNG groups.
DCIS Features
Among the 55 cases of DCIS, 24 (44%) were non-HNG and 31 (56%) were HNG ( Table 1 ). The sizes of the DCIS on MR imaging ranged from 6.0 mm to 133.8 mm with a mean size of 32.7 mm. There was no significant difference in size between the non-HNG and HNG groups (P 5 0.76). The majority (n 5 44/55; 80%) of the DCIS presented as NME on MR imaging; among them were 17 (71%) of the 24 non-HNG DCIS and 27 (87%) of the 31 HNG DCIS. Except for a single case of an enhancing focus (n 5 1/55; 2%), which represented non-HNG DCIS, the remaining cases presented as masses (n 5 10/55; 18%), including 6 (25%) of the 24 non-HNG DCIS and 4 (13%) of the 31 HNG DCIS. There was no significant difference in the MR imaging lesion types between the non-HNG and HNG groups (P 5 0.24).
All of the non-HNG disease stained positive for ER and none were positive (IHC 31) for HER2 amplification (Table 1) . In contrast, 20 of 31 (65%) of the HNG cases were ER positive and nearly a third (10/31, 32%) of HNG cases showed positive HER2 amplification. There were only a total of five confirmed triple negative/basal-like cases, all of which were HNG DCIS. The differences in the percentages of ER and HER2 positivity between non-HNG and HNG groups were statistically significant (P 0.001).
Heterogeneity Correlation With DCIS Grade, ER Status, and HER2 Amplification
The voxel counts of the 55 ROIs ranged from 32 to 54,393, with a median of 365. Figures 1 and 2 demonstrated two sample cases of non-HNG and HNG DCIS, respectively, with the color-mapped ROIs representing enhancing disease on the postcontrast sequences. One metric, surface-to-volume ratio, showed a significant difference between non-HNG and HNG DCIS on precontrast, first postcontrast, fourth postcontrast, and subtracted first postcontrast images (Table 2) . Three heterogeneity metrics approached statistically significant differences between non-HNG and HNG disease on the subtracted fourth postcontrast images: Surface-to-volume ratio, low graylevel run emphasis, and short run low gray-level run emphasis ( Table 3 ). The results of selective important metrics, including those that demonstrate and approach statistical significance, are summarized in box plots for the first postcontrast sequence (Fig. 3A) and the fourth postcontrast sequence (Fig. 3B) . After excluding the purely intermediate-grade DCIS (n 5 10) from the non-HNG group to compare the low nuclear grade (LNG, n 5 14; low and low-to-intermediate grade) versus HNG groups, the same single metric, surface-to-volume ratio, remained significantly different for the same MR sequences (Table 3) . On the other hand, excluding intermediate-grade cases increased the total number of heterogeneity metrics that approached significant differences (P < 0.1) between LNG and HNG DCIS to seven. These seven metrics included four additional metrics: Minimal intensity, skewness, kurtosis, and correlation (Table 3) .
No metrics showed statistical significance in differentiating ER positive from ER negative DCIS, whereas multiple metrics were found significantly different between HER2 positive and HER2 negative disease (Table 2) .
In detail, 5 metrics on the precontrast images, 7 metrics on the first postcontrast images, 2 metrics on the fourth postcontrast images, 10 metrics on the subtracted first postcontrast images, and 2 metrics on the subtracted fourth postcontrast images were significantly different between DCIS with and DCIS without HER2 amplification (Table  2 ). In total, 17 of 57 significant metrics were identified in the heterogeneity analysis of HER2 positive versus HER2 negative DCIS (Table 2 ). These metrics include short run emphasis, which was significantly different in all five imaging sequences (precontrast, first and fourth postcontrast, and subtracted first and fourth postcontrast sequences) and five additional metrics (minimum intensity, median intensity, mean deviation, standard deviation, and variance) that were significantly different in at least two of the five imaging sequences (Table 2) . Percentage enhancement did not show significant differences between HER2 positive versus HER2 negative DCIS (Table 2) .
Discussion
In recent years, applications of heterogeneity analysis have demonstrated the potential of MR imaging biomarkers in improving the specificity of breast MR and providing clinically relevant biological indicators of invasive breast cancers. [22] [23] [24] [25] [26] [27] [28] Until now, heterogeneity analysis has not been used in the development of MR imaging biomarkers of DCIS. Our study investigates the technique of computeraided heterogeneity analysis in the characterization of DCIS and suggests the presence of MR imaging biomarkers in classifying DCIS nuclear grade and HER2 status. Slightly more than half of our cases were intermediateto-high-grade or high-grade DCIS, corroborating prior work by Kuhl and colleagues, which showed a greater sensitivity of MR imaging in the detection of intermediate and highgrade DCIS compared with mammography and increased sensitivity of MR imaging in the detection of DCIS with higher nuclear grade.
14 HNG DCIS carries important prognostic impact, as they tend to progress more frequently and rapidly to invasive cancer that are more likely high grade. 2, 33 HNG DCIS also appears to respond differently to treatment compared with its low-grade counterpart. 4, 5 None of the conventional MR imaging parameters and descriptors that were analyzed showed a significant difference between HNG and non-HNG DCIS. MR BI-RADS lexicons that describe enhancement morphology, that is, mass, NME, and focus, did not significantly differ between HNG and non-HNG DCIS. Additionally, heterogeneity metrics that represented conventional size assessments by imaging, such as maximum 3D diameter, voxel count, and volume did not show any significant correlation with DCIS grade or receptor status. These findings were in accordance with prior research. Previously, Esserman and colleagues demonstrated that the combination of tumor distribution and enhancement characteristics on MR imaging reflected the underlying histopathology of DCIS. 34 Yet, no significant correlation was identified between any single imaging variable with either nuclear grade or proliferative index, Ki67. 34 These results suggested that our current unaided visual perception and interpretation of MR imaging is inadequate to decode the biological variability of DCIS. Computer-aided heterogeneity analysis could, therefore, provide objective, quantitative, higher level imaging biomarkers to supplement existing knowledge and this current study adds important information to this investigation. Nonetheless, only one heterogeneity metric, surface-tovolume ratio, was significantly different between HNG and non-HNG DCIS. On average, HNG DCIS has a smaller surface-to-volume ratio than non-HNG disease. The biological basis and implication of this metric is unclear. A smaller surface-to-volume ratio would indicate that HNG DCIS is more compact, more consolidated, and higher in pixel density on imaging. Previous work revealed that pathologic tumor density significantly correlated with MR imaging density. 34 As such, we could speculate that this metric depicts the tightly packed rapid expansion and overgrowth of HNG DCIS, in contrast with the more porous, noncontiguous, gradual spread of non-HNG DCIS. Of interest, a total of 17 metrics showed significant differences between HER2 positive and HER2 negative diseases. Among these metrics, short-run emphasis was significantly greater in value for HER2 negative DCIS compared with HER2 positive disease across all five MR sequences. A short run-length consists of few consecutive pixels of the same gray-level intensity in a particular direction. 35 Fine texture is populated by shorter runs. 35 Therefore, a greater measure of short-run emphasis indicated an overall finer texture of HER2 negative DCIS relative to HER2 amplified disease. Four metrics analyzing signal intensity values, minimal, maximum, mean, and median intensity, showed an average lower pixel intensity in HER2 positive DCIS compared with HER2 negative disease. However, these values did not take into consideration the transmitter gain, filter, or undergo normalization. As such, percentage enhancement represents a more meaningful imaging biomarker, as it is normalized with respect to the absolute signal intensity of the precontrast images from the same examination and potentially reflects angiogenesis related to HER2 amplification, where observation of a relationship between MR imaging enhancement and the microvascular pattern of DCIS has been previously described. 36 Positive association of HER2 amplification with periductal neovascularization has also been reported. 37 Nevertheless, we found no statistically significant correlation of percentage enhancement with HER2 amplification status. Currently, HER2 amplification is not routinely tested in DCIS because its clinical or prognostic relevance is not yet elucidated. 38, 39 HER2 amplification is strongly associated with HNG, and as mentioned above, HNG DCIS is independently associated with increased recurrence and progression to invasive disease. 2, 33, 38 Two thirds of the imaging biomarkers that correlated with HER2 amplification were identified on the first postcontrast or subtracted first postcontrast sequences. This finding is revealing given that DCIS tends to demonstrate persistent enhancement kinetics and, therefore, DCIS often enhances most intensely on the delayed (fourth) postcontrast images. Yet only three metrics were identified on the fourth or subtracted fourth postcontrast sequences. These results emphasize the importance of the initial (first) postcontrast sequence, which likely presents the most accurate manifestation of the underlying pathophysiology for possibly both invasive cancers and DCIS. Of interest, 5 of the 17 metrics were shown on the precontrast images. This observation suggests that noncontrast imaging potentially contains more information than we traditionally perceive.
Limitations of this study include its retrospective methodology and small sample size. Additionally, 13 of the 55 cases (23.6%) of DCIS were biopsied before MR imaging, which could have affected some of the imaging metrics. A couple of reasons may have contributed to the lack of additional biomarkers in differentiating nuclear grades. The study may have been underpowered to detect significance in the remaining metrics. Alternatively, the binary classification of HNG and non-HNG groups may not be biologically relevant or appropriate. To address this possible explanation, we reclassified the nuclear grades into the LNG and HNG groups by excluding the intermediate-grade DCIS. We had hoped that the more biologically distinct separation of the two groups in terms of nuclear grades would identify more imaging biomarkers from heterogeneity analysis. The results showed the same single significant metric in differentiating nuclear grade, although more metrics approached statistical significance after the LNG versus HNG subdivision. This finding suggests that with larger sample sizes, these imaging metrics could demonstrate significant associations in differentiating LNG from HNG DCIS.
Similar explanations could account for the lack of correlation of heterogeneity metrics with ER status. Larger studies with a more enriched population of ER negative DCIS may unveil significant metrics. Our study had only five cases of confirmed triple negative/basal-like DCIS.
With a larger sample, analysis based on luminal versus basal-like molecular subtypes may be more biologically relevant. As expected, ER negativity, HER2 amplification, and presence of necrosis correlated with HNG in the study.
Our univariate comparisons presented important exploratory results, which will require further validation with additional patients given that the heterogeneity features are high dimensional. While mathematical and imaging analytical definitions of the heterogeneity metrics have been well described, 31 potential underlying biologic or pathophysiologic significance of these features requires further illumination. Future work with larger populations that allow for correlation with molecular subtypes and Oncotype DX DCIS scores is expected. Correlation of imaging heterogeneity features with long-term outcomes such as invasive recurrence may be achievable with much larger data sets. Based on the established MR imaging biomarkers, a machinelearning algorithm could then be developed to prospectively assess or predict the underlying DCIS tumor biology.
In conclusion, our study illustrates the feasibility and potential value of the use of computer-aided heterogeneity analysis in evaluating DCIS. Identification of MR imaging biomarkers helps increase the prognostic value of DCE MR imaging and may ultimately provide a noninvasive means to better understand the variable biological behavior of DCIS.
